Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: Results from the ACTIVE phase 3 trial.

Miller PD, Hattersley G, Lau E, Fitzpatrick LA, Harris AG, Williams GC, Hu MY, Riis BJ, Russo L, Christiansen C

Bone22 Oct 2018Cited by 54 (Europe PMC)

PMID30359763DOI10.1016/j.bone.2018.10.015PepBankPUB-30359763

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study15

15 results from studies that gave the peptide. 15 results from people.

01HumanRandomized controlled trialEfficacy outcome
In women with postmenopausal osteoporosis, 19.1% with abaloparatide versus 0.9% with placebo gained >3% BMD at all three skeletal sites at month 6.
In plain wordsIn women with osteoporosis, abaloparatide had more responders than placebo for >3% bone density gains at all three sites.
Peptide
Abaloparatide (Tymlos)
Outcome
Increase>3% BMD responders at month 6
Study
n: not reported in source
Comparator
Placebo
Analysis
Exploratory
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Measurements
Proportion of >3% BMD responders at month 6
19.1%
abaloparatide
Proportion of >3% BMD responders at month 6
0.9%
placebo
Source sentences
Summary
At months 6, 12, and 18, there were significantly more >3% BMD responders in the abaloparatide group compared with placebo and teriparatide: month 6, 19.1% vs 0.9% for placebo and 6.5% for teriparatide; month 12, 33.2% vs 1.5% and 19.8%; month 18, 44.5% vs 1.9% and 32.0% (P < 0.001 for all compariso…
3 context sentences(design, population, supporting numbers)
Summary · context
Here, we report a prospective, exploratory BMD responder analysis from ACTIVE.
Summary · context
Proportions of patients experiencing BMD gains from baseline of >0%, >3%, and >6% at the total hip, femoral neck, and lumbar spine at 6, 12, and 18 months of treatment were compared among the placebo, abaloparatide, and teriparatide groups in ACTIVE.
Summary · context
Responders were defined prospectively as patients experiencing BMD gains at all 3 anatomic sites.
Report a problemFND-3035976301
02HumanRandomized controlled trialEfficacy outcome
In women with postmenopausal osteoporosis, 19.1% with abaloparatide versus 6.5% with teriparatide gained >3% BMD at all three skeletal sites at month 6.
In plain wordsIn women with osteoporosis, abaloparatide had more responders than teriparatide for >3% bone density gains at all three sites.
Peptide
Abaloparatide (Tymlos)
Outcome
Increase>3% BMD responders at month 6
Study
n: not reported in source
Comparator
Teriparatide
Analysis
Exploratory
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Measurements
Proportion of >3% BMD responders at month 6
19.1%
abaloparatide
Proportion of >3% BMD responders at month 6
6.5%
teriparatide
Source sentences
Summary
At months 6, 12, and 18, there were significantly more >3% BMD responders in the abaloparatide group compared with placebo and teriparatide: month 6, 19.1% vs 0.9% for placebo and 6.5% for teriparatide; month 12, 33.2% vs 1.5% and 19.8%; month 18, 44.5% vs 1.9% and 32.0% (P < 0.001 for all compariso…
3 context sentences(design, population, supporting numbers)
Summary · context
Here, we report a prospective, exploratory BMD responder analysis from ACTIVE.
Summary · context
Proportions of patients experiencing BMD gains from baseline of >0%, >3%, and >6% at the total hip, femoral neck, and lumbar spine at 6, 12, and 18 months of treatment were compared among the placebo, abaloparatide, and teriparatide groups in ACTIVE.
Summary · context
Responders were defined prospectively as patients experiencing BMD gains at all 3 anatomic sites.
Report a problemFND-3035976302
03HumanRandomized controlled trialEfficacy outcome
In women with postmenopausal osteoporosis, 33.2% with abaloparatide versus 1.5% with placebo gained >3% BMD at all three skeletal sites at month 12.
In plain wordsIn women with osteoporosis, abaloparatide had more responders than placebo for >3% bone density gains at all three sites.
Peptide
Abaloparatide (Tymlos)
Outcome
Increase>3% BMD responders at month 12
Study
n: not reported in source
Comparator
Placebo
Analysis
Exploratory
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Measurements
Proportion of >3% BMD responders at month 12
33.2%
abaloparatide
Proportion of >3% BMD responders at month 12
1.5%
placebo
Source sentences
Summary
At months 6, 12, and 18, there were significantly more >3% BMD responders in the abaloparatide group compared with placebo and teriparatide: month 6, 19.1% vs 0.9% for placebo and 6.5% for teriparatide; month 12, 33.2% vs 1.5% and 19.8%; month 18, 44.5% vs 1.9% and 32.0% (P < 0.001 for all compariso…
3 context sentences(design, population, supporting numbers)
Summary · context
Here, we report a prospective, exploratory BMD responder analysis from ACTIVE.
Summary · context
Proportions of patients experiencing BMD gains from baseline of >0%, >3%, and >6% at the total hip, femoral neck, and lumbar spine at 6, 12, and 18 months of treatment were compared among the placebo, abaloparatide, and teriparatide groups in ACTIVE.
Summary · context
Responders were defined prospectively as patients experiencing BMD gains at all 3 anatomic sites.
Report a problemFND-3035976303
04HumanRandomized controlled trialEfficacy outcome
In women with postmenopausal osteoporosis, 33.2% with abaloparatide versus 19.8% with teriparatide gained >3% BMD at all three skeletal sites at month 12.
In plain wordsIn women with osteoporosis, abaloparatide had more responders than teriparatide for >3% bone density gains at all three sites.
Peptide
Abaloparatide (Tymlos)
Outcome
Increase>3% BMD responders at month 12
Study
n: not reported in source
Comparator
Teriparatide
Analysis
Exploratory
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Measurements
Proportion of >3% BMD responders at month 12
33.2%
abaloparatide
Proportion of >3% BMD responders at month 12
19.8%
teriparatide
Source sentences
Summary
At months 6, 12, and 18, there were significantly more >3% BMD responders in the abaloparatide group compared with placebo and teriparatide: month 6, 19.1% vs 0.9% for placebo and 6.5% for teriparatide; month 12, 33.2% vs 1.5% and 19.8%; month 18, 44.5% vs 1.9% and 32.0% (P < 0.001 for all compariso…
3 context sentences(design, population, supporting numbers)
Summary · context
Here, we report a prospective, exploratory BMD responder analysis from ACTIVE.
Summary · context
Proportions of patients experiencing BMD gains from baseline of >0%, >3%, and >6% at the total hip, femoral neck, and lumbar spine at 6, 12, and 18 months of treatment were compared among the placebo, abaloparatide, and teriparatide groups in ACTIVE.
Summary · context
Responders were defined prospectively as patients experiencing BMD gains at all 3 anatomic sites.
Report a problemFND-3035976304
05HumanRandomized controlled trialEfficacy outcome
In women with postmenopausal osteoporosis, 44.5% with abaloparatide versus 1.9% with placebo gained >3% BMD at all three skeletal sites at month 18.
In plain wordsIn women with osteoporosis, abaloparatide had more responders than placebo for >3% bone density gains at all three sites.
Peptide
Abaloparatide (Tymlos)
Outcome
Increase>3% BMD responders at month 18
Study
n: not reported in source
Comparator
Placebo
Analysis
Exploratory
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Measurements
Proportion of >3% BMD responders at month 18
44.5%
abaloparatide
Proportion of >3% BMD responders at month 18
1.9%
placebo
Source sentences
Summary
At months 6, 12, and 18, there were significantly more >3% BMD responders in the abaloparatide group compared with placebo and teriparatide: month 6, 19.1% vs 0.9% for placebo and 6.5% for teriparatide; month 12, 33.2% vs 1.5% and 19.8%; month 18, 44.5% vs 1.9% and 32.0% (P < 0.001 for all compariso…
3 context sentences(design, population, supporting numbers)
Summary · context
Here, we report a prospective, exploratory BMD responder analysis from ACTIVE.
Summary · context
Proportions of patients experiencing BMD gains from baseline of >0%, >3%, and >6% at the total hip, femoral neck, and lumbar spine at 6, 12, and 18 months of treatment were compared among the placebo, abaloparatide, and teriparatide groups in ACTIVE.
Summary · context
Responders were defined prospectively as patients experiencing BMD gains at all 3 anatomic sites.
Report a problemFND-3035976305
06HumanRandomized controlled trialEfficacy outcome
In women with postmenopausal osteoporosis, 44.5% with abaloparatide versus 32.0% with teriparatide gained >3% BMD at all three skeletal sites at month 18.
In plain wordsIn women with osteoporosis, abaloparatide had more responders than teriparatide for >3% bone density gains at all three sites.
Peptide
Abaloparatide (Tymlos)
Outcome
Increase>3% BMD responders at month 18
Study
n: not reported in source
Comparator
Teriparatide
Analysis
Exploratory
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Measurements
Proportion of >3% BMD responders at month 18
44.5%
abaloparatide
Proportion of >3% BMD responders at month 18
32%
teriparatide
Source sentences
Summary
At months 6, 12, and 18, there were significantly more >3% BMD responders in the abaloparatide group compared with placebo and teriparatide: month 6, 19.1% vs 0.9% for placebo and 6.5% for teriparatide; month 12, 33.2% vs 1.5% and 19.8%; month 18, 44.5% vs 1.9% and 32.0% (P < 0.001 for all compariso…
3 context sentences(design, population, supporting numbers)
Summary · context
Here, we report a prospective, exploratory BMD responder analysis from ACTIVE.
Summary · context
Proportions of patients experiencing BMD gains from baseline of >0%, >3%, and >6% at the total hip, femoral neck, and lumbar spine at 6, 12, and 18 months of treatment were compared among the placebo, abaloparatide, and teriparatide groups in ACTIVE.
Summary · context
Responders were defined prospectively as patients experiencing BMD gains at all 3 anatomic sites.
Report a problemFND-3035976306
07HumanRandomized controlled trialEfficacy outcome
In women with postmenopausal osteoporosis, abaloparatide had more responders with >0% BMD gains at all three skeletal sites than placebo.
In plain wordsIn women with osteoporosis, abaloparatide had more responders than placebo for >0% bone density gains at all three sites.
Peptide
Abaloparatide (Tymlos)
Outcome
Increase>0% BMD responders
Study
n: not reported in source
Comparator
Placebo
Analysis
Exploratory
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
Findings were similar for the >0% and >6% responder thresholds.
4 context sentences(design, population, supporting numbers)
Summary · context
At months 6, 12, and 18, there were significantly more >3% BMD responders in the abaloparatide group compared with placebo and teriparatide: month 6, 19.1% vs 0.9% for placebo and 6.5% for teriparatide; month 12, 33.2% vs 1.5% and 19.8%; month 18, 44.5% vs 1.9% and 32.0% (P < 0.001 for all compariso…
Summary · context
Here, we report a prospective, exploratory BMD responder analysis from ACTIVE.
Summary · context
Proportions of patients experiencing BMD gains from baseline of >0%, >3%, and >6% at the total hip, femoral neck, and lumbar spine at 6, 12, and 18 months of treatment were compared among the placebo, abaloparatide, and teriparatide groups in ACTIVE.
Summary · context
Responders were defined prospectively as patients experiencing BMD gains at all 3 anatomic sites.
Report a problemFND-3035976310
08HumanRandomized controlled trialEfficacy outcome
In women with postmenopausal osteoporosis, abaloparatide had more responders with >0% BMD gains at all three skeletal sites than teriparatide.
In plain wordsIn women with osteoporosis, abaloparatide had more responders than teriparatide for >0% bone density gains at all three sites.
Peptide
Abaloparatide (Tymlos)
Outcome
Increase>0% BMD responders
Study
n: not reported in source
Comparator
Teriparatide
Analysis
Exploratory
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
Findings were similar for the >0% and >6% responder thresholds.
4 context sentences(design, population, supporting numbers)
Summary · context
At months 6, 12, and 18, there were significantly more >3% BMD responders in the abaloparatide group compared with placebo and teriparatide: month 6, 19.1% vs 0.9% for placebo and 6.5% for teriparatide; month 12, 33.2% vs 1.5% and 19.8%; month 18, 44.5% vs 1.9% and 32.0% (P < 0.001 for all compariso…
Summary · context
Here, we report a prospective, exploratory BMD responder analysis from ACTIVE.
Summary · context
Proportions of patients experiencing BMD gains from baseline of >0%, >3%, and >6% at the total hip, femoral neck, and lumbar spine at 6, 12, and 18 months of treatment were compared among the placebo, abaloparatide, and teriparatide groups in ACTIVE.
Summary · context
Responders were defined prospectively as patients experiencing BMD gains at all 3 anatomic sites.
Report a problemFND-3035976311
09HumanRandomized controlled trialEfficacy outcome
In women with postmenopausal osteoporosis, abaloparatide had more responders with >6% BMD gains at all three skeletal sites than placebo.
In plain wordsIn women with osteoporosis, abaloparatide had more responders than placebo for >6% bone density gains at all three sites.
Peptide
Abaloparatide (Tymlos)
Outcome
Increase>6% BMD responders
Study
n: not reported in source
Comparator
Placebo
Analysis
Exploratory
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
Findings were similar for the >0% and >6% responder thresholds.
4 context sentences(design, population, supporting numbers)
Summary · context
At months 6, 12, and 18, there were significantly more >3% BMD responders in the abaloparatide group compared with placebo and teriparatide: month 6, 19.1% vs 0.9% for placebo and 6.5% for teriparatide; month 12, 33.2% vs 1.5% and 19.8%; month 18, 44.5% vs 1.9% and 32.0% (P < 0.001 for all compariso…
Summary · context
Here, we report a prospective, exploratory BMD responder analysis from ACTIVE.
Summary · context
Proportions of patients experiencing BMD gains from baseline of >0%, >3%, and >6% at the total hip, femoral neck, and lumbar spine at 6, 12, and 18 months of treatment were compared among the placebo, abaloparatide, and teriparatide groups in ACTIVE.
Summary · context
Responders were defined prospectively as patients experiencing BMD gains at all 3 anatomic sites.
Report a problemFND-3035976312
10HumanRandomized controlled trialEfficacy outcome
In women with postmenopausal osteoporosis, abaloparatide had more responders with >6% BMD gains at all three skeletal sites than teriparatide.
In plain wordsIn women with osteoporosis, abaloparatide had more responders than teriparatide for >6% bone density gains at all three sites.
Peptide
Abaloparatide (Tymlos)
Outcome
Increase>6% BMD responders
Study
n: not reported in source
Comparator
Teriparatide
Analysis
Exploratory
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
Findings were similar for the >0% and >6% responder thresholds.
4 context sentences(design, population, supporting numbers)
Summary · context
At months 6, 12, and 18, there were significantly more >3% BMD responders in the abaloparatide group compared with placebo and teriparatide: month 6, 19.1% vs 0.9% for placebo and 6.5% for teriparatide; month 12, 33.2% vs 1.5% and 19.8%; month 18, 44.5% vs 1.9% and 32.0% (P < 0.001 for all compariso…
Summary · context
Here, we report a prospective, exploratory BMD responder analysis from ACTIVE.
Summary · context
Proportions of patients experiencing BMD gains from baseline of >0%, >3%, and >6% at the total hip, femoral neck, and lumbar spine at 6, 12, and 18 months of treatment were compared among the placebo, abaloparatide, and teriparatide groups in ACTIVE.
Summary · context
Responders were defined prospectively as patients experiencing BMD gains at all 3 anatomic sites.
Report a problemFND-3035976313
11HumanObservational studyEfficacy outcome
In women with postmenopausal osteoporosis, 6.5% with teriparatide versus 19.1% with abaloparatide gained >3% BMD at all three skeletal sites at month 6.
In plain wordsIn women with osteoporosis, teriparatide had fewer responders than abaloparatide for >3% bone density gains at all three sites.
Peptide
Teriparatide (PTH 1-34)
Outcome
Decrease>3% BMD responders at month 6
Study
n: not reported in source
Comparator
Abaloparatide
Analysis
Exploratory
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Measurements
Proportion of >3% BMD responders at month 6
6.5%
teriparatide
Proportion of >3% BMD responders at month 6
19.1%
abaloparatide
Source sentences
Summary
At months 6, 12, and 18, there were significantly more >3% BMD responders in the abaloparatide group compared with placebo and teriparatide: month 6, 19.1% vs 0.9% for placebo and 6.5% for teriparatide; month 12, 33.2% vs 1.5% and 19.8%; month 18, 44.5% vs 1.9% and 32.0% (P < 0.001 for all compariso…
3 context sentences(design, population, supporting numbers)
Summary · context
Here, we report a prospective, exploratory BMD responder analysis from ACTIVE.
Summary · context
Proportions of patients experiencing BMD gains from baseline of >0%, >3%, and >6% at the total hip, femoral neck, and lumbar spine at 6, 12, and 18 months of treatment were compared among the placebo, abaloparatide, and teriparatide groups in ACTIVE.
Summary · context
Responders were defined prospectively as patients experiencing BMD gains at all 3 anatomic sites.
Report a problemFND-3035976307
12HumanObservational studyEfficacy outcome
In women with postmenopausal osteoporosis, 19.8% with teriparatide versus 33.2% with abaloparatide gained >3% BMD at all three skeletal sites at month 12.
In plain wordsIn women with osteoporosis, teriparatide had fewer responders than abaloparatide for >3% bone density gains at all three sites.
Peptide
Teriparatide (PTH 1-34)
Outcome
Decrease>3% BMD responders at month 12
Study
n: not reported in source
Comparator
Abaloparatide
Analysis
Exploratory
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Measurements
>3% BMD responders at month 12
19.8%
teriparatide group
>3% BMD responders at month 12
33.2%
abaloparatide group (comparator)
Source sentences
Summary
At months 6, 12, and 18, there were significantly more >3% BMD responders in the abaloparatide group compared with placebo and teriparatide: month 6, 19.1% vs 0.9% for placebo and 6.5% for teriparatide; month 12, 33.2% vs 1.5% and 19.8%; month 18, 44.5% vs 1.9% and 32.0% (P < 0.001 for all compariso…
3 context sentences(design, population, supporting numbers)
Summary · context
Here, we report a prospective, exploratory BMD responder analysis from ACTIVE.
Summary · context
Proportions of patients experiencing BMD gains from baseline of >0%, >3%, and >6% at the total hip, femoral neck, and lumbar spine at 6, 12, and 18 months of treatment were compared among the placebo, abaloparatide, and teriparatide groups in ACTIVE.
Summary · context
Responders were defined prospectively as patients experiencing BMD gains at all 3 anatomic sites.
Report a problemFND-3035976308
13HumanObservational studyEfficacy outcome
In women with postmenopausal osteoporosis, 32.0% with teriparatide versus 44.5% with abaloparatide gained >3% BMD at all three skeletal sites at month 18.
In plain wordsIn women with osteoporosis, teriparatide had fewer responders than abaloparatide for >3% bone density gains at all three sites.
Peptide
Teriparatide (PTH 1-34)
Outcome
Decrease>3% BMD responders at month 18
Study
n: not reported in source
Comparator
Abaloparatide
Analysis
Exploratory
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Measurements
>3% BMD responders at month 18
32%
teriparatide group
>3% BMD responders at month 18
44.5%
abaloparatide group (comparator)
Source sentences
Summary
At months 6, 12, and 18, there were significantly more >3% BMD responders in the abaloparatide group compared with placebo and teriparatide: month 6, 19.1% vs 0.9% for placebo and 6.5% for teriparatide; month 12, 33.2% vs 1.5% and 19.8%; month 18, 44.5% vs 1.9% and 32.0% (P < 0.001 for all compariso…
3 context sentences(design, population, supporting numbers)
Summary · context
Here, we report a prospective, exploratory BMD responder analysis from ACTIVE.
Summary · context
Proportions of patients experiencing BMD gains from baseline of >0%, >3%, and >6% at the total hip, femoral neck, and lumbar spine at 6, 12, and 18 months of treatment were compared among the placebo, abaloparatide, and teriparatide groups in ACTIVE.
Summary · context
Responders were defined prospectively as patients experiencing BMD gains at all 3 anatomic sites.
Report a problemFND-3035976309
14HumanObservational studyEfficacy outcome
In women with postmenopausal osteoporosis, teriparatide had fewer responders with >0% BMD gains at all three skeletal sites than abaloparatide.
In plain wordsIn women with osteoporosis, teriparatide had fewer responders than abaloparatide for >0% bone density gains at all three sites.
Peptide
Teriparatide (PTH 1-34)
Outcome
Decrease>0% BMD responders
Study
n: not reported in source
Comparator
Abaloparatide
Analysis
Exploratory
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
Findings were similar for the >0% and >6% responder thresholds.
4 context sentences(design, population, supporting numbers)
Summary · context
At months 6, 12, and 18, there were significantly more >3% BMD responders in the abaloparatide group compared with placebo and teriparatide: month 6, 19.1% vs 0.9% for placebo and 6.5% for teriparatide; month 12, 33.2% vs 1.5% and 19.8%; month 18, 44.5% vs 1.9% and 32.0% (P < 0.001 for all compariso…
Summary · context
Here, we report a prospective, exploratory BMD responder analysis from ACTIVE.
Summary · context
Proportions of patients experiencing BMD gains from baseline of >0%, >3%, and >6% at the total hip, femoral neck, and lumbar spine at 6, 12, and 18 months of treatment were compared among the placebo, abaloparatide, and teriparatide groups in ACTIVE.
Summary · context
Responders were defined prospectively as patients experiencing BMD gains at all 3 anatomic sites.
Report a problemFND-3035976314
15HumanObservational studyEfficacy outcome
In women with postmenopausal osteoporosis, teriparatide had fewer responders with >6% BMD gains at all three skeletal sites than abaloparatide.
In plain wordsIn women with osteoporosis, teriparatide had fewer responders than abaloparatide for >6% bone density gains at all three sites.
Peptide
Teriparatide (PTH 1-34)
Outcome
Decrease>6% BMD responders
Study
n: not reported in source
Comparator
Abaloparatide
Analysis
Exploratory
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
Findings were similar for the >0% and >6% responder thresholds.
4 context sentences(design, population, supporting numbers)
Summary · context
At months 6, 12, and 18, there were significantly more >3% BMD responders in the abaloparatide group compared with placebo and teriparatide: month 6, 19.1% vs 0.9% for placebo and 6.5% for teriparatide; month 12, 33.2% vs 1.5% and 19.8%; month 18, 44.5% vs 1.9% and 32.0% (P < 0.001 for all compariso…
Summary · context
Here, we report a prospective, exploratory BMD responder analysis from ACTIVE.
Summary · context
Proportions of patients experiencing BMD gains from baseline of >0%, >3%, and >6% at the total hip, femoral neck, and lumbar spine at 6, 12, and 18 months of treatment were compared among the placebo, abaloparatide, and teriparatide groups in ACTIVE.
Summary · context
Responders were defined prospectively as patients experiencing BMD gains at all 3 anatomic sites.
Report a problemFND-3035976315

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 2
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: Results from the ACTIVE phase 3 trial.

Summary

Results from this study15

Version history

Subjects

Publication types

MeSH terms

Keywords